智通财经APP获悉，艾迪康控股(09860)涨超5%，截至发稿，涨5.23%，报7.64港元，成交额615.13万港元。
消息面上，今年1月，首都医科大学临床检验中心与艾迪康达成战略合作，双方将共同探讨精准医学检验和病理诊断发展需求及医产学研合作模式，以推动创新诊断技术成果转化与临床应用，提高医疗服务质量。华创证券此前指出，国内ICL市场渗透率相较于国外仍有较大差距，在分级诊疗推进、医保控费压力加大、DRG/DIP付费方式改革、基层医疗建设的推动下，国内ICL行业有望进入快速发展期。
去年12月，艾迪康控股公布，董事会决定利用购回授权在公开市场购回不多于3628.72万股股份，占已发行股份总数的约5%，购回价格最高为每股9.69港元。建议股份购回将由公司内部资源提供资金。公司将根据购回股份时的市况及其资本管理需求，随后注销购回股份或将其持作库存股。董事会认为，于现况下进行股份购回可展示公司对自身业务展望及前景充满信心，且最终会为公司带来裨益及为股东创造价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.